Cargando…
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
BACKGROUND AND OBJECTIVE: To avoid insulin-induced hypoglycemia and weight gain, the minimum dose of insulin should be used. In this study, therefore, we examined insulin dose reduction by ipragliflozin add-on therapy in Japanese patients with type 2 diabetes mellitus treated with long-acting basal...
Autores principales: | Ishihara, Hisamitsu, Yamaguchi, Susumu, Sugitani, Toshifumi, Kosakai, Yoshinori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842350/ https://www.ncbi.nlm.nih.gov/pubmed/31552641 http://dx.doi.org/10.1007/s40261-019-00851-z |
Ejemplares similares
-
Efficacy and safety of ipragliflozin as add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi‐centre, randomized, placebo‐controlled, double‐blind study
por: Ishihara, Hisamitsu, et al.
Publicado: (2016) -
Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
por: Ishihara, Hisamitsu, et al.
Publicado: (2018) -
Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020) -
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials
por: Kashiwagi, Atsunori, et al.
Publicado: (2016) -
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal‐bolus insulin therapy: An open‐label, single‐center, parallel, randomized control study
por: Okajima, Fumitaka, et al.
Publicado: (2016)